crizotinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4187 877399-52-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • crizotinib
  • xalkori
  • PF 02341066
  • PF-02341066
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d'Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene's expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.
  • Molecular weight: 450.34
  • Formula: C21H22Cl2FN5O
  • CLOGP: 4.29
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 77.99
  • ALOGS: -4.87
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 22.15 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.75 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.09 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 38.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 23, 2012 EMA
Aug. 26, 2011 FDA PF PRISM CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 801.68 24.30 379 8810 90921 46585952
Neoplasm progression 728.15 24.30 251 8938 26432 46650441
Non-small cell lung cancer 445.58 24.30 107 9082 3037 46673836
Lung neoplasm malignant 411.41 24.30 143 9046 15346 46661527
Death 324.78 24.30 362 8827 335186 46341687
Photopsia 241.11 24.30 69 9120 3907 46672966
Visual impairment 224.67 24.30 148 9041 66541 46610332
Nausea 193.24 24.30 418 8771 687036 45989837
Vomiting 124.75 24.30 274 8915 452520 46224353
Pleural effusion 109.05 24.30 106 9083 82846 46594027
Dysgeusia 103.61 24.30 76 9113 40415 46636458
Renal abscess 101.75 24.30 24 9165 627 46676246
Constipation 89.10 24.30 138 9051 173959 46502914
Oedema peripheral 87.95 24.30 131 9058 159575 46517298
Oesophagitis 87.44 24.30 46 9143 13605 46663268
Diarrhoea 84.57 24.30 271 8918 559331 46117542
Vitreous floaters 76.71 24.30 31 9158 5014 46671859
Pneumonitis 65.22 24.30 50 9139 28370 46648503
Interstitial lung disease 59.94 24.30 63 9126 53886 46622987
Neoplasm malignant 57.58 24.30 43 9146 23456 46653417
Oedema 50.37 24.30 64 9125 67007 46609866
Drug ineffective 48.19 24.30 38 9151 677800 45999073
Lung adenocarcinoma 41.39 24.30 19 9170 4185 46672688
Dysphagia 39.03 24.30 61 9128 77251 46599622
Decreased appetite 38.68 24.30 104 9085 193732 46483141
Non-small cell lung cancer metastatic 38.49 24.30 11 9178 618 46676255
Embolism 37.22 24.30 21 9168 7117 46669756
Multiple-drug resistance 36.39 24.30 15 9174 2550 46674323
Transaminases increased 35.51 24.30 35 9154 27726 46649147
Drug resistance 34.34 24.30 28 9161 17340 46659533
Acquired gene mutation 34.25 24.30 10 9179 606 46676267
Pericardial effusion 34.16 24.30 33 9156 25510 46651363
Renal cyst 33.24 24.30 21 9168 8738 46668135
Drug hypersensitivity 31.78 24.30 5 9184 243820 46433053
Vision blurred 31.03 24.30 56 9133 79652 46597221
Metastases to central nervous system 30.80 24.30 22 9167 11199 46665674
Bradycardia 30.29 24.30 50 9139 66248 46610625
Oesophageal pain 29.85 24.30 13 9176 2530 46674343
Visual brightness 29.63 24.30 5 9184 20 46676853
Hepatotoxicity 29.18 24.30 30 9159 24979 46651894
Pulmonary embolism 27.67 24.30 64 9125 108521 46568352
Oesophageal ulcer 27.22 24.30 14 9175 3947 46672926
Bronchial carcinoma 24.90 24.30 8 9181 669 46676204
Alanine aminotransferase increased 24.61 24.30 54 9135 88397 46588476

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 765.21 26.09 368 6468 79506 29866136
Neoplasm progression 579.85 26.09 199 6637 17824 29927818
Non-small cell lung cancer 416.75 26.09 108 6728 3622 29942020
Death 346.83 26.09 413 6423 356870 29588772
Lung neoplasm malignant 299.57 26.09 117 6719 15015 29930627
Visual impairment 113.12 26.09 76 6760 30362 29915280
Nausea 84.40 26.09 199 6637 296758 29648884
Neoplasm malignant 72.24 26.09 47 6789 17767 29927875
Oedema peripheral 62.40 26.09 97 6739 105735 29839907
Photopsia 58.08 26.09 20 6816 1786 29943856
Interstitial lung disease 53.11 26.09 67 6769 60130 29885512
Lung adenocarcinoma 51.62 26.09 23 6813 4076 29941566
Diarrhoea 48.21 26.09 176 6660 333927 29611715
Drug ineffective 45.51 26.09 11 6825 340376 29605266
Constipation 44.90 26.09 87 6749 112819 29832823
Dysgeusia 43.96 26.09 40 6796 24761 29920881
Oesophagitis 41.69 26.09 28 6808 11143 29934499
Pneumonitis 38.65 26.09 39 6797 27415 29918227
Oedema 38.12 26.09 48 6788 42945 29902697
Lung adenocarcinoma stage IV 38.07 26.09 8 6828 103 29945539
Vomiting 32.57 26.09 117 6719 219701 29725941
Pleural effusion 31.78 26.09 59 6777 74007 29871635
Hypoalbuminaemia 30.32 26.09 23 6813 11069 29934573
Second primary malignancy 28.80 26.09 18 6818 6338 29939304
Non-small cell lung cancer stage IV 28.01 26.09 7 6829 201 29945441
Decreased appetite 26.76 26.09 85 6751 149825 29795817
Metastases to central nervous system 26.56 26.09 18 6818 7266 29938376

Pharmacologic Action:

SourceCodeDescription
ATC L01ED01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Anaplastic lymphoma kinase (ALK) inhibitors
FDA MoA N0000020000 Receptor Tyrosine Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA MoA N0000182139 Cytochrome P450 2B6 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000187061 Organic Cation Transporter 2 Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000191265 Organic Cation Transporter 1 Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:62434 alk inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Non-small cell lung cancer indication 254637007 DOID:3908

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.74 Basic
pKa2 6.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL March 11, 2023 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
250MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL March 11, 2023 TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
200MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL Jan. 14, 2024 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
250MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL Jan. 14, 2024 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
200MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL Jan. 14, 2028 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
250MG XALKORI PF PRISM CV N202570 Aug. 26, 2011 RX CAPSULE ORAL Jan. 14, 2028 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANULLPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
ALK tyrosine kinase receptor Kinase INHIBITOR Ki 9.13 CHEMBL CHEMBL
Hepatocyte growth factor receptor Kinase INHIBITOR Kd 9.26 CHEMBL CHEMBL
SRSF protein kinase 1 Kinase Kd 5.74 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6.68 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.68 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 8 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.48 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.64 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.64 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 6.25 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.21 CHEMBL
Insulin receptor Kinase AGONIST Kd 6.47 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 5.40 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.40 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.48 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 6.05 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 6.24 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6.54 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 5.34 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.55 CHEMBL
Aurora kinase A Kinase Kd 6.59 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 6.48 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.60 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 5.11 CHEMBL
Cyclin-dependent kinase 11B Kinase Kd 6.12 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.64 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.16 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.24 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.41 CHEMBL
AarF domain-containing protein kinase 4 Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.29 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.74 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.54 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.36 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 7.22 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.64 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.70 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.11 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.96 CHEMBL
Aurora kinase C Kinase Kd 5.37 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 7.02 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 5.43 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.11 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 5.44 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 6.43 CHEMBL
Misshapen-like kinase 1 Kinase Kd 5.36 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 5.44 CHEMBL
Insulin receptor-related protein Kinase Kd 6.22 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 6.10 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6.13 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 6.11 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 7.19 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
Aurora kinase B Kinase Kd 7.12 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.74 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 6.64 CHEMBL
Macrophage-stimulating protein receptor Kinase Kd 7.60 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.68 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 7.31 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 6.24 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.33 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase Kd 5.26 CHEMBL
Serine/threonine-protein kinase Nek9 Kinase Kd 6.10 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.03 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 5.62 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 5.44 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6 CHEMBL
LIM domain kinase 1 Kinase Kd 6.08 CHEMBL
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) Kinase IC50 7.29 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 5.80 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 6.44 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.92 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 6.12 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 7.12 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 6.42 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.51 CHEMBL
NT-3 growth factor receptor Kinase Kd 7.09 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.38 CHEMBL
Activin receptor type-1 Kinase Kd 6.36 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 7.51 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.38 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.14 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.17 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6.34 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.55 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 6.72 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.96 CHEMBL
Angiopoietin-1 receptor Kinase Kd 6.57 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.15 CHEMBL
Peripheral plasma membrane protein CASK Kinase Kd 6.85 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 6.35 CHEMBL
Proto-oncogene tyrosine-protein kinase ROS Kinase Kd 8.39 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 8.22 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.70 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.96 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.48 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 5.48 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.89 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 6.68 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 6.62 CHEMBL
Activin receptor type-1B Kinase Kd 6.07 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6.96 CHEMBL
TGF-beta receptor type-1 Kinase Kd 6 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 5.89 CHEMBL
Myotonin-protein kinase Kinase Kd 5.85 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.29 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 6.10 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.35 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.52 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 7.92 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 6.01 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 8.11 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 7.43 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.92 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.09 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 6.07 CHEMBL
LIM domain kinase 2 Kinase Kd 6.16 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.77 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 5.80 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.49 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.96 CHEMBL
Cyclin-dependent kinase 11A Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.21 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 6 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 7.10 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 8.44 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 6.29 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 7 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.49 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 6.15 CHEMBL
Angiopoietin-1 receptor Kinase IC50 6.35 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 5.94 CHEMBL
Macrophage-stimulating protein receptor Kinase IC50 7.10 CHEMBL

External reference:

IDSource
4030983 VUID
N0000183253 NUI
D09731 KEGG_DRUG
4030983 VANDF
C2974289 UMLSCUI
CHEBI:64310 CHEBI
VGH PDB_CHEM_ID
CHEMBL601719 ChEMBL_ID
DB08865 DRUGBANK_ID
D000077547 MESH_DESCRIPTOR_UI
11626560 PUBCHEM_CID
4903 IUPHAR_LIGAND_ID
9301 INN_ID
53AH36668S UNII
1148495 RXNORM
185331 MMSL
28080 MMSL
d07800 MMSL
013917 NDDF
703637000 SNOMEDCT_US
703638005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xalkori HUMAN PRESCRIPTION DRUG LABEL 1 0069-8140 CAPSULE 250 mg ORAL NDA 32 sections
Xalkori HUMAN PRESCRIPTION DRUG LABEL 1 0069-8141 CAPSULE 200 mg ORAL NDA 32 sections